At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 244 enrolled
Drug / intervention
Cilostazol +1 moredrug
Likely dose
Cilostazol 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 4 Study of Additional Cilostazol for Overcoming Biochemical Aspirin Resistance in the Chronic Stroke Patients
In Brief
A Phase 4 clinical trial evaluating Cilostazol and placebo for Cerebral Infarction. Completed, enrolled 244 participants across 4 sites.
Detailed Summary
This study will recruit 316 ischemic stroke patients taking aspirin. They will be randomly assigned into cilostazol group or placebo group. Every patients will take 200mg of cilostazol a day or placebo for 1 month. The primary outcome variable of this study is rate of biochemical aspirin resistance on the Ultra Rapid Platelet Function Assay-ASA.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Infarction
CountriesSouth Korea
CollaboratorsKorea Otsuka Pharmaceutical Co., Ltd.
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMar 2007
Primary CompletionJun 2008
Study CompletionJul 2008
TodayJul 2026
First PostedMar 13, 2007
Enrollment StartMar 1, 2007
Primary CompletionJun 1, 2008
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.3 years ago
Interventions
Cilostazoldrug
cilostazol 100mg twice a day for 4 weeks
placebodrug
placebo 1 tablet twice a day matching for cilostazol